COVID-19 and Vitamin D: Length of Hospital Stay and Mortality

Vitamin D Deficiency Clinical Trial

Official title:

Vitamin D Level: Reflections of a Public Health Issue in the COVID-19 Pandemic. Does it Affect Mortality and Length of Hospital Stay?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05221983
• Other study ID #: YuksekIU-SCOZBEK001
• Status: Completed
• Start date: August 21, 2021
• Est. completion date: November 16, 2021

Study information

• Verified date: February 2022
• Source: Yuksek Ihtisas University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.

Description:

This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study.

The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 168
• Est. completion date: November 16, 2021
• Est. primary completion date: November 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19 PCR (Polymerase Chain Reaction) test positive

• Vitamin D level in biochemical parameters

• Adult patients hospitalized for COVID-19

Exclusion Criteria:

-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Pandemic
• Vitamin D Deficiency

Locations

Country	Name	City	State
Turkey	Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital	Ankara

Sponsors (2)

Lead Sponsor	Collaborator
Yuksek Ihtisas University	Ankara City Hospital Bilkent

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of Vitamin D	Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.	1 month later
Primary	Relationship between vitamin D level and mortality	Relationship between survival and death by categorized vitamin D level.	1 month later
Primary	Relationship between vitamin D level and hospital stay	Length of hospital stay by categorized vitamin D level.	1 month later
Secondary	Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality	Evaluation of the impact of comorbidities on survival during COVID-19 disease.	1 month later.